CagriSema: Side Effects
Known side effects, contraindications, and interactions
📌TL;DR
- •5 known side effects documented
- •5 mild, 0 moderate, 0 severe
- •3 contraindications listed
Compare side effects across multiple peptides →
Side Effects Severity Chart
Most common adverse event. Reported in approximately 55% of CagriSema participants in REDEFINE 1. Generally mild to moderate, most common during dose escalation, and tends to improve with continued treatment.
Common GI adverse event during dose escalation. Generally transient and mild to moderate. Higher rate than semaglutide alone due to additive amylin-mediated gastric emptying delay.
Commonly reported GI adverse event. Usually mild to moderate and self-limiting.
Related to slowed GI transit from dual amylin and GLP-1 receptor activation.
Injection site reactions including erythema, pain, and pruritus. Generally mild and may be slightly higher than semaglutide alone due to the combination formulation.
⛔Contraindications
- •Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) -- GLP-1 agonist class
- •Pregnancy (semaglutide component)
- •Prior serious hypersensitivity to cagrilintide, semaglutide, or excipients
⚠️Drug Interactions
- •Insulin and sulfonylureas: Increased risk of hypoglycemia when combined (GLP-1 agonist class interaction)
- •Oral contraceptives: Gastric emptying delay from dual amylin/GLP-1 activation may reduce absorption
- •Oral medications with narrow therapeutic index: Slowed gastric emptying may affect absorption of warfarin, digoxin, levothyroxine
Community-Reported Side Effects
See which side effects community members report most frequently.
Based on 15+ community reports
View community protocolsSafety Overview#
CagriSema's safety profile has been characterized in the REDEFINE Phase 3 program enrolling over 4,600 participants. The adverse event profile is consistent with the combined GLP-1 and amylin agonist mechanisms, with GI events being most common. In REDEFINE 1, GI adverse events occurred in 79.6% of CagriSema patients versus 39.9% with placebo, though the majority were transient and mild to moderate.
Gastrointestinal Adverse Events#
The dual mechanism of CagriSema (both amylin and GLP-1 receptor activation) produces GI effects through additive gastric emptying delay and central appetite suppression.
REDEFINE 1 Safety Profile#
GI adverse events were the most frequently reported category:
- Overall GI adverse events: 79.6% (CagriSema) vs 39.9% (placebo)
- Nausea: Approximately 55% of CagriSema participants
- Vomiting, diarrhea, constipation: Common but mostly mild to moderate
Most GI events were:
- Transient in nature
- Mild to moderate in severity
- Most common during the dose escalation phase
- Tended to resolve with continued treatment at maintenance dose
Comparison with Semaglutide Alone#
GI adverse event rates with CagriSema are somewhat higher than semaglutide alone, which is expected given the additive gastric emptying effects of amylin receptor activation. However, the discontinuation rate due to adverse events remained relatively low.
Treatment Discontinuation#
Discontinuation rates due to adverse events were relatively low in the REDEFINE trials:
- CagriSema: 6-8.4%
- Placebo: Lower
These rates are comparable to other GLP-1 agonist therapies and suggest that the combination is generally well tolerated despite the higher absolute GI event rates.
GLP-1 and Amylin Agonist Class Warnings#
Thyroid C-Cell Tumors#
The semaglutide component of CagriSema carries the GLP-1 agonist class boxed warning for thyroid C-cell tumors. CagriSema is expected to carry the same contraindication for patients with MTC or MEN2 history.
Pancreatitis#
Both GLP-1 agonists and amylin analogs have been associated with pancreatitis reports. Patients should report persistent severe abdominal pain.
Gallbladder Disease#
The substantial weight loss produced by CagriSema (20.4% in REDEFINE 1) increases the risk of cholelithiasis and cholecystitis.
Injection Site Reactions#
As a subcutaneous injectable, CagriSema may cause injection site reactions including erythema, pain, and pruritus. These are generally mild and comparable to other injectable peptide therapies.
Heart Rate Effects#
GLP-1 agonists typically increase resting heart rate by 2-4 bpm. The impact of the additional amylin receptor activation on heart rate with CagriSema has not been separately characterized.
Contraindications (Expected)#
Based on the GLP-1 agonist class and semaglutide labeling:
- MTC/MEN2: Absolute contraindication
- Pregnancy: Should not be used during pregnancy; discontinue before planned conception
- Hypersensitivity: Prior serious reaction to either component
Drug Interactions#
- Insulin and sulfonylureas: Dose reduction may be needed due to hypoglycemia risk
- Oral medications: The dual gastric emptying delay from amylin and GLP-1 agonism may affect absorption of co-administered oral drugs more than semaglutide alone
- Oral contraceptives: Consider non-oral contraception during initiation
Special Populations#
Full data on renal impairment, hepatic impairment, elderly, and pediatric populations will be available in prescribing information upon regulatory approval.
Related Reading#
Unlock full side effects analysis
Free access to detailed safety profiles and interaction guidance for all peptides.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About CagriSema
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.